Device and Drug as One Product: VOCERYQ, CELLECTRA and the Commercial Test for DNA Medicines
Dr. Dereck Mush, MD, MBA
INOVIO Pharmaceuticals
DNA medicines company behind VOCERYQ, granted FDA accelerated approval on October 30, 2026.
What they do
INOVIO (Nasdaq: INO) develops DNA medicines. FDA granted accelerated approval to VOCERYQ on October 30, 2026, to reduce the frequency of surgical papilloma excisions in adults with recurrent respiratory papillomatosis. FDA describes it as the first plasmid DNA-based immunotherapy approved in the United States. Continued approval may depend on confirmation of clinical benefit.
The record
- Vertical
- Pharma & Drug Discovery
- Sub-segment
- DNA medicines
- Product type
- Platform software
- Stage
- Public
- Headquarters
- Plymouth Meeting, Pennsylvania, USA
- Region
- North America
- Founded
- Not disclosed
- Total funding
- Undisclosed
Also in Pharma & Drug Discovery
Related on The Signal
Dr. Dereck Mush, MD, MBA
What Pharma Is Buying From AI Drug Discovery: Inside AstraZeneca’s insitro Deal
Dr. Dereck Mush, MD, MBAThe HealthTech Signal
Chai Discovery triples its valuation as pharma buys into AI-designed molecules
Chai Discovery triples its valuation as pharma buys into AI-designed molecules
Dr. Dereck Mush, MD, MBA
The $2.4B Oral Macrocycle and Bispecific Surge: Why Big Pharma Is Buying Platform Engines Over Single Assets
Dr. Dereck Mush, MD, MBA